PC Connection, Inc. (CNXN) Forms $25.27 Double Bottom; Axogen (AXGN) Shorts Raised By 0.87%

Axogen Incorporated (NASDAQ:AXGN) had an increase of 0.87% in short interest. AXGN’s SI was 984,200 shares in February as released by FINRA. Its up 0.87% from 975,700 shares previously. With 502,100 avg volume, 2 days are for Axogen Incorporated (NASDAQ:AXGN)’s short sellers to cover AXGN’s short positions. The SI to Axogen Incorporated’s float is 4.27%. The stock increased 1.86% or $0.5 during the last trading session, reaching $27.4. About 265,230 shares traded. AxoGen, Inc. (NASDAQ:AXGN) has risen 181.49% since February 16, 2017 and is uptrending. It has outperformed by 164.79% the S&P500.

PC Connection, Inc. (CNXN) formed double bottom with $24.01 target or 5.00% below today’s $25.27 share price. PC Connection, Inc. (CNXN) has $677.63 million valuation. The stock decreased 0.51% or $0.13 during the last trading session, reaching $25.27. About 29,588 shares traded. PC Connection, Inc. (NASDAQ:CNXN) has risen 18.98% since February 16, 2017 and is uptrending. It has outperformed by 2.28% the S&P500.

AxoGen, Inc. provides surgical solutions for peripheral nerve injuries. The company has market cap of $934.17 million. The companyÂ’s surgical nerve repair solutions include Avance Nerve Graft, an off-the-shelf processed human nerve allograft for bridging severed nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix coaptation aid for tensionless repair of severed nerves; and AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect injured peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments. It currently has negative earnings. The Company’s solutions also comprise Avive Soft Tissue Membrane, a minimally processed human umbilical cord membrane that is used as a resorbable soft tissue covering to separate tissues and modulate inflammation in the surgical bed.

Among 8 analysts covering AxoGen (NASDAQ:AXGN), 8 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. AxoGen had 18 analyst reports since August 11, 2015 according to SRatingsIntel. The rating was upgraded by Zacks on Tuesday, August 11 to “Hold”. As per Monday, September 11, the company rating was maintained by Roth Capital. The stock has “Buy” rating by Cantor Fitzgerald on Monday, January 8. As per Tuesday, November 21, the company rating was maintained by Wedbush. The firm earned “Outperform” rating on Monday, November 7 by Wedbush. As per Friday, August 28, the company rating was maintained by Wedbush. Lake Street upgraded AxoGen, Inc. (NASDAQ:AXGN) on Tuesday, November 22 to “Buy” rating. The stock of AxoGen, Inc. (NASDAQ:AXGN) has “Outperform” rating given on Thursday, November 2 by Leerink Swann. Leerink Swann maintained the stock with “Outperform” rating in Tuesday, November 21 report. The rating was downgraded by Lake Street on Thursday, November 3 to “Hold”.